Investors

Best-in-Class Treatment for DDD

Notogen presents a unique opportunity to invest in the expansive spine, orthopedic and sports medicine therapeutic technology space. A profound void exists in the continuum of care related to non-surgical intervention for back pain. NTG-101 is positioned to address this void with a simple, cost-effective solution. Notogen has secured investment to achieve near-term goals and is currently seeking additional investment to support future milestones.

Events & Presentations

Oct 2020

Virtual
BIO Investor Forum

Oct 2020

Virtual
Animal Health Investment USA – Innovation Showcase

Oct 2020

Virtual
North American Spine Society (NASS) 35th Annual Meeting

Best Paper Award: “The effects of a single injection of NTG-101 upon neurotrophin expression in a canine model of degenerative disc disease”
Podium Presentation: “Study comparing NTG-101, a growth factor-based therapy with mesenchymal stem cell (MSC) based treatment of degenerative disc disease (DDD) in pre-clinical rodent model”

Jun 2020

Virtual
BIO International Convention

Jun 2020

Philadelphia, PA
Redefining Early Stage Investments Conference – Innovation Challenge Finalist

Feb 2020

Niagara, ON
2020 Niagara Investment Summit

Oct 2018

Chicago, IL
2018 Biologic: Interventions for Spinal Pathologies: Stem Cells, Growth Factors & Novel Therapeutics

Sep 2018

Los Angeles, CA
North American Spine Society (NASS) 33rd Annual Meeting

Nov 2017

Toronto, ON
LLC 5th Annual Ehlers-Danlos & Chronic Pain Conference